Cited by 1,248Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenomics and Rare Diseases

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The IARC TP53 database: New online mutation analysis and recommendations to users

Open access

Olivier, Magali, Eeles, Ros, Hollstein, Monica, Khan, Mohammed A., Harris, Curtis C., Hainaut, Pierre·2002·Human Mutation

DOI 10.1002/humu.10081

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/humu.10081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Greenblatt, 1994, Cancer Res, 54, 4855
Hollstein, 1994, Nucleic Acids Res, 22, 3551
Vahteristo, 2001, Cancer Res, 61, 5718

Sorted by citations

Items 401–500 of 1,000

Human Breast Tumor Cells Are More Resistant to Cardiac Glycoside Toxicity Than Non-Tumorigenic Breast Cells
Clifford, R. J., & Kaplan, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084306 · Cited by 45
Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53
Quinn, B. A., Brake, T., Xiang, H., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008404 · Cited by 46
Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo
Kamat, C. D., Shmueli, R. B., Connis, N., Rudin, C. M., Green, J. J., & Hann, C. L. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0956 · Cited by 45
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins
Golovenko, D., Bräuning, B., Vyas, P., Haran, T. E., Rozenberg, H., & Shakked, Z. (2018) · Structure · doi:10.1016/j.str.2018.06.006 · Cited by 44
Tumor Suppressor Protein p53 Regulates Megakaryocytic Polyploidization and Apoptosis
Fuhrken, P. G., Apostolidis, P. A., Lindsey, S. C., Miller, W. M., & Papoutsakis, E. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801923200 · Cited by 45
Mutations in p53, p53 protein overexpression and breast cancer survival
Rössner, P., Gammon, M. D., Zhang, Y., Terry, M. B., Hibshoosh, H. H., Memeo, L., MANSUKHANI, M. M., Long, C., Garbowski, G. C., Agrawal, M., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00553.x · Cited by 45
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
5-Aza-2′-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation
Scott, S. A., Dong, W.-F., Ichinohasama, R., Hirsch, C. L., Sheridan, D. P., Sanche, S. E., Geyer, C. R., & DeCoteau, J. F. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.05.010 · Cited by 44
Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells
Zhang, J., Zhang, S., Song, J., Sun, K., Zong, C., Zhao, Q., Liu, W., Li, R., Wu, M., & Wei, L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.009 · Cited by 45
Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival
Salmoiraghi, S., Montalvo, M. L. G., Ubiali, G., Tosi, M., Peruta, B., Zanghi, P., Oldani, E., Boschini, C., Kohlmann, A., Bungaro, S., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.137059 · Cited by 44
Novel synthesised flavone derivatives provide significant insight into the structural features required for enhanced anti-proliferative activity
Ravishankar, D., Watson, K. A., Greco, F., & Osborn, H. M. I. (2016) · RSC Advances · doi:10.1039/c6ra11041j · Cited by 44
GSAR: Bioconductor package for Gene Set analysis in R
Rahmatallah, Y., Zybailov, B. L., Emmert‐Streib, F., & Glazko, G. V. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1482-6 · Cited by 42
Markov state models and NMR uncover an overlooked allosteric loop in p53
de Barros, E. P., Demir, Ö., Soto, J., Cocco, M. J., & Amaro, R. E. (2020) · Chemical Science · doi:10.1039/d0sc05053a · Cited by 45
Chapter 7 Aristolochic Acid Nephropathy
Grollman, A. P., Scarborough, J., & Jelaković, B. (2009) · Advances in molecular toxicology · doi:10.1016/s1872-0854(09)00007-1 · Cited by 44
Mutational analysis of PDGFR–RAS/MAPK pathway activation in childhood medulloblastoma
Gilbertson, R. J., Langdon, J. A., Hollander, A. B., Hernán, R., Hogg, T. L., Gajjar, A. J., Fuller, C. E., & Clifford, S. C. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.023 · Cited by 44
Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: Case report with immunohistochemical and mutational analysis
Han, B., Mori, I., Nakamura, M., Wang, X., Ozaki, T., Nakamura, Y., & Kakudo, K. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01948.x · Cited by 44
Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay
Monti, P., Campomenosi, P., Ciribilli, Y., Iannone, R., Aprile, A., Inga, A., Tada, M., Menichini, P., Abbondandolo, A., & Fronza, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206511 · Cited by 44
Significance of CpG Methylation for Solar UV‐Induced Mutagenesis and Carcinogenesis in Skin‡
Ikehata, H., & Ono, T. (2006) · Photochemistry and Photobiology · doi:10.1562/2006-02-28-ir-822 · Cited by 46
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin
Kanashiro, C. A., Schally, A. V., Groot, K., Armatis, P. E., Bernardino, A., & Varga, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536558100 · Cited by 44
Arsenic promotes centrosome abnormalities and cell colony formation in p53 compromised human lung cells
Liao, W., Lin, P., Cheng, T.-S., Yu, H., & Chang, L. W. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.07.017 · Cited by 43
Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72
Reinbold, M., Luo, J.-L., Nedelko, T., Jerchow, B., Murphy, M. E., Whibley, C. E., Wei, Q., & Hollstein, M. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210932 · Cited by 43
p53-based therapeutics for head and neck squamous cell carcinoma
Tassone, P. T., Old, M. O., Teknos, T. N., & Pan, Q. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.447 · Cited by 43
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas
Hayes, J. L., Yu, Y., Jalbert, L. E., Mazor, T., Jones, L. E., Wood, M. D., Walsh, K. M., Bengtsson, H. L., Hong, C., Oberndorfer, S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox205 · Cited by 43
Selective Pressures at a Codon-level Predict Deleterious Mutations in Human Disease Genes
Arbiza, L., Duchi, S., Montaner, D. A., Burguet, J., Pantoja‐Uceda, D., Pineda‐Lucena, A., Dopazo, J., & Dopazo, H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.02.067 · Cited by 42
Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients
Jeon, C., Lee, H.-I., Shin, I.-H., & Park, J. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-007-0373-0 · Cited by 43
The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma.
Kankuri‐Tammilehto, M., Söderström, K., Pelliniemi, T., Vahlberg, T. J., Pyrhönen, S. O., & Salminen, E. K. (2006) · PubMed · Cited by 43
Patches of Mutant p53-Immunoreactive Epidermal Cells Induced by Chronic UVB Irradiation Harbor the Same p53 Mutations as Squamous Cell Carcinomas in the Skin of Hairless SKH-1 Mice
Kramata, P., Lu, Y., Lou, Y.-R., Singh, R. N., Kwon, S. M., & Conney, A. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4537 · Cited by 43
Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature
Butler, J. S., & Loh, S. N. (2006) · Protein Science · doi:10.1110/ps.062324206 · Cited by 44
Structural Effects of the L145Q, V157F, and R282W Cancer-Associated Mutations in the p53 DNA-Binding Core Domain
Calhoun, S., & Daggett, V. (2011) · Biochemistry · doi:10.1021/bi200192j · Cited by 42
Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors
Zhang, H., Wang, H., Zhang, J., Qian, G., Niu, B., Fan, X., Lu, J., Hoffman, A. R., Hu, J., & Ge, S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.236 · Cited by 42
Conformational stability and dynamics of the cancer‐associated isoform Δ133p53β are modulated by p53 peptides and p53‐specific DNA
Lei, J., Qi, R., Tang, Y., Wang, W., Wei, G., Nussinov, R., & Ma, B. (2018) · The FASEB Journal · doi:10.1096/fj.201801973r · Cited by 45
DNA microarrays on a dendron-modified surface improve significantly the detection of single nucleotide variations in the p53 gene
Oh, S. J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni087 · Cited by 42
Metformin Suppresses Pancreatic Tumor Growth With Inhibition of NFκB/STAT3 Inflammatory Signaling
Tan, X., Bhattacharyya, K. K., Dutta, S. K., Bamlet, W. R., Rabe, K. G., Wang, E., Smyrk, T. C., Oberg, A. L., Petersen, G. M., & Mukhopadhyay, D. (2015) · Pancreas · doi:10.1097/mpa.0000000000000308 · Cited by 41
Nobiletin Induces Apoptosis and Potentiates the Effects of the Anticancer Drug 5-Fluorouracil in p53-Mutated SNU-16 Human Gastric Cancer Cells
Moon, J. Y., Cho, M., Ahn, K. S., & Cho, S. K. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.756529 · Cited by 42
p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis
Cescon, D. W., Bradbury, P. A., Asomaning, K., Hopkins, J. J., Zhai, R., Zhou, W., Wang, Z., Kulke, M. H., Su, L., Ma, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3120 · Cited by 41
Apoptosis in Carcinogenesis and Chemotherapy
Chen, G. G., & Lai, P. B. S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9597-9 · Cited by 49
Kinetic Partitioning During Folding of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.060 · Cited by 41
Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes
Mühlbauer, K.-R., Gröne, H., Ernst, T., Gröne, E. F., Tschada, R., Hergenhahn, M., & Hollstein, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601164 · Cited by 41
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma
Masterson, L. M., Moualed, D., Masood, A., Dwivedi, R. C., Benson, R. J., Sterling, J. C., Rhodes, K. M., Sudhoff, H. H., Jani, P., & Goon, P. K. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010271.pub2 · Cited by 40
Multi-targeted approach in the treatment of thyroid cancer
Chen, H. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3062 · Cited by 40
Bladder cancer subtypes defined by genomic alterations
Knowles, M. A. (2008) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/03008880802284605 · Cited by 41
Functional Census of Mutation Sequence Spaces: The Example of p53 Cancer Rescue Mutants
Danziger, S. A., Swamidass, S. J., Zeng, J., Dearth, L. R., Lü, Q., Chen, J. H., Cheng, J., Hoang, V. P., Saigo, H., Luo, R., et al. (2006) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2006.22 · Cited by 40
Intrinsic disorder in proteins: a challenge for (un)structural biology met by ion mobility–mass spectrometry
Jurneczko, E., Cruickshank, F. L., Porrini, M., Nikolova, P. V., Campuzano, I. D. G., Morris, M. R., & Barran, P. E. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120125 · Cited by 40
CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling
Narayanaswamy, P. B., Tkachuk, S., Haller, H. G., Dumler, I., & Kiyan, Y. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.291 · Cited by 40
p53mutations associated with aging-related rise in cancer incidence rates
Richardson, R. B. (2013) · Cell Cycle · doi:10.4161/cc.25494 · Cited by 41
Molecular biology of bladder cancer
Luis, N. M., López‐Knowles, E., & Real, F. X. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0003-x · Cited by 40
p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder, J. C., Conway, K., Yu, L., Mistry, K., Bell, D. A., & Taylor, J. A. (2003) · PubMed · Cited by 40
Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer
Akkіprіk, M., Sonmez, O., Gulluoglu, B. M., Çağlar, H. B., Kaya, H., Demirkalem, P., Abacıoğlu, U., Şengöz, M., Sav, A., & Özer, A. (2008) · Pathology & Oncology Research · doi:10.1007/s12253-008-9129-6 · Cited by 39
Overlapping Group Logistic Regression with Applications to Genetic Pathway Selection
Zeng, Y., & Breheny, P. J. (2016) · Cancer Informatics · doi:10.4137/cin.s40043 · Cited by 40
Potential therapeutic targets ofTP53gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer
Tanaka, T., Watanabe, M., & Yamashita, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24611 · Cited by 46
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B
Labban, D. A., Jo, S., Ostano, P., Saglietti, C., Bongiovanni, M., Panizzon, R. G., & Dotto, G. P. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96915 · Cited by 39
Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations
Li, L., Li, X., Tang, Y., Lao, Z., Lei, J., & Wei, G. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp06671c · Cited by 40
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents
Leiba, M., Jakubı́ková, J., Klippel, S., Mitsiades, C. S., Hideshima, T., Tai, Y., Leiba, A., Pines, M., Richardson, P. G. G., Nagler, A., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09120.x · Cited by 39
The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy
Seemann, S., Maurici, D., Olivier, M., de Fromentel, C. C., & Hainaut, P. L. (2004) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360490504952 · Cited by 39
Genetic Alterations in Cancer Knowledge System: Analysis of Gene Mutations in Mouse and Human Liver and Lung Tumors
Jackson, M. A., Lea, I. A., Rashid, A., Peddada, S. D., & Dunnick, J. K. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj101 · Cited by 39
Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer
Hassan, N. M. M., Tada, M., Hamada, J.-I., Kashiwazaki, H., Kameyama, T., Akhter, R., Yamazaki, Y., Yano, M., Inoue, N., & Moriuchi, T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.052 · Cited by 39
Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population
Yamada, H., Shinmura, K., Okudela, K., Goto, M., Suzuki, M., Kuriki, K., Tsuneyoshi, T., & Sugimura, H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm175 · Cited by 39
TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma.
Moreno, M., Pimentel, F., Gazdar, A. F., Wistuba, I. I., & Miquel, J. F. (2005) · PubMed · Cited by 39
β-Lapachone Significantly Increases the Effect of Ionizing Radiation to Cause Mitochondrial Apoptosis via JNK Activation in Cancer Cells
Park, M., Song, M.-J., Lee, H., Oh, E., Choi, B., Jeong, S., Choi, E., & Park, H. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025976 · Cited by 40
N-Isopropylacrylamide-modified polyethylenimine-mediated p53 gene delivery to prevent the proliferation of cancer cells
Zhang, J., Wu, D., Xing, Z., Liang, S., Han, H., Shi, H., Zhang, Y., Yang, Y., & Li, Q. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.03.032 · Cited by 38
Differential response between the p53 ubiquitin–protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells
Duan, W., Gao, L., Wu, X., Zhang, Y., Otterson, G. A., & Villalona-Calero, M. A. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.07.005 · Cited by 38
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency
Shapira, I., Lee, A., Vora, R. K., & Budman, D. R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.003 · Cited by 41
Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review
Dickman, K. G., Chen, C., Grollman, A. P., & Pu, Y. (2022) · World Journal of Urology · doi:10.1007/s00345-022-04100-5 · Cited by 38
TP53 Abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma§
Moreno, M., Pimentel, F., Gazdar, A. F., Wistuba, I. I., & Miquel, J. F. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32065-4 · Cited by 38
Preferential Binding of Hot Spot Mutant p53 Proteins to Supercoiled DNA In Vitro and in Cells
Brázdová, M., Navrátilová, L., Tichý, V., Němcová, K., Lexa, M., Hrstka, R., Pečínka, P., Adámik, M., Vojtěšek, B., Paleček, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059567 · Cited by 38
Immunological characterization of missense mutations occurring within cytotoxic T cell‐defined p53 epitopes in HLA‐A*0201 + squamous cell carcinomas of the head and neck
Ito, D., Visús, C., Hoffmann, T. K., Balz, V., Bier, H., Appella, E., Whiteside, T. L., Ferris, R. L., & DeLeo, A. B. (2007) · International Journal of Cancer · doi:10.1002/ijc.22584 · Cited by 37
Functional analysis of p53 gene and the prognostic impact of dominant‐negative p53 mutation in endometrial cancer
Sakuragi, N., Watari, H., Ebina, Y., Yamamoto, R., Steiner, E., Koelbl, H., Yano, M., Tada, M., & Moriuchi, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21097 · Cited by 37
DNA Damage, Repair, and Mutation Induction by (+)- Syn and (−)- Anti -Dibenzo[ a,l ]Pyrene-11,12-Diol-13,14-Epoxides in Mouse Cells
Yoon, J.-H., Nia, A. B., Feng, Z., Tang, M.-S., Amin, S., Luch, A., & Pfeifer, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1094 · Cited by 37
Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers
Hagiwara, N., Mechanic, L. E., Trivers, G. E., Cawley, H., Taga, M., Bowman, E. D., Kumamoto, K., He, P., Bernard, M., Doja, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0991 · Cited by 37
Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
Xiao, M., Zhang, L., Zhu, X., Huang, J., Jiang, H., Hu, S., & Liu, Y. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-147 · Cited by 36
Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines
Baldini, E., Tuccilli, C., Prinzi, N., Sorrenti, S., Antonelli, A., Gnessi, L., Morrone, S., Moretti, C., Bononi, M., Arlot‐Bonnemains, Y., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0299 · Cited by 36
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals
Abrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.06.002 · Cited by 36
Transcriptional networks orchestrating programmed cell death during plant development
Cubría-Radío, M., & Nowack, M. K. (2018) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2018.10.006 · Cited by 35
Overexpression of WRAP53 Is Associated with Development and Progression of Esophageal Squamous Cell Carcinoma
Rao, X., Huang, D.-F., Sui, X., Liu, G., Song, X., Xie, J., & Huang, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091670 · Cited by 36
Taking Human Cancer Genes to the Fish: A Transgenic Model of Melanoma in Zebrafish
Patton, E. E., & Zon, L. I. (2005) · Zebrafish · doi:10.1089/zeb.2005.1.363 · Cited by 36
Somatic alterations of the p53 tumor suppressor gene in vaccine-associated feline sarcoma
Banerji, N., & Kanjilal, S. (2006) · American Journal of Veterinary Research · doi:10.2460/ajvr.67.10.1766 · Cited by 36
Identification of a Dominant Negative Functional Domain on DAPK-1 That Degrades DAPK-1 Protein and Stimulates TNFR-1-mediated Apoptosis
Lin, Y., Stevens, C., & Hupp, T. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611559200 · Cited by 36
Mutation spectrum in sunlight-exposed mouse skin epidermis: small but appreciable contribution of oxidative stress-mediated mutagenesis
Ikehata, H., Nakamura, S., Asamura, T., & Ono, T. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.06.038 · Cited by 37
Gal‐3 is stimulated by gain‐of‐function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas
Lavra, L., Ulivieri, A., Rinaldo, C., Dominici, R., Volante, M., Luciani, E., Bartolazzi, A., Frasca, F., Soddu, S., & Sciacchitano, S. (2008) · The Journal of Pathology · doi:10.1002/path.2510 · Cited by 36
Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles
Santos, K., Laranjo, M., Abrantes, A. M., Brito, A., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Botelho, M. F., Soares, M. I. L., Oliveira, A. S. R., & Melo, T. M. V. D. P. E. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.008 · Cited by 35
Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation
Ponce‐Cusi, R., & Calaf, G. M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3298 · Cited by 38
Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53
Kichina, J. V., Rauth, S., Gupta, T. K. D., & Gudkov, A. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206741 · Cited by 33
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Figueroa, J. D., Terry, M. B., Gammon, M. D., Vaughan, T. L., Risch, H. A., Zhang, F. F., Kleiner, D. E., Bennett, W. P., Howe, C. L., Dubrow, R., et al. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9250-6 · Cited by 35
Hypermutable bases in the p53 cancer gene are at vulnerable positions in DNA secondary structures.
Wright, B. E., Reimers, J. M., Schmidt, K. H., & Reschke, D. K. (2002) · PubMed · Cited by 35
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249
Shi, H., Lambert, J. M. R., Hautefeuille, A. H., Bykov, V. J. N., Wiman, K. G., Hainaut, P. L., & de Fromentel, C. C. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm266 · Cited by 35
Id4 dependent acetylation restores mutant-p53 transcriptional activity
Knowell, A. E., Patel, D., Morton, D. J., Sharma, P., Glymph, S., & Chaudhary, J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-161 · Cited by 35
Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma
Bäckvall, H., Strömberg, S., Gustafsson, A. C., Asplund, A., Sivertsson, Å., Lundeberg, J., & Pontén, F. (2004) · Experimental Dermatology · doi:10.1111/j.0906-6705.2004.00211.x · Cited by 35
TP53 mutations in workers exposed to occupational carcinogens
Vähäkangas, K. (2003) · Human Mutation · doi:10.1002/humu.10182 · Cited by 35
Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice
Krepulat, F., Löhler, J., Heinlein, C., Hermannstädter, A., Tolstonog, G. V., & Deppert, W. (2005) · Oncogene · doi:10.1038/sj.onc.1208557 · Cited by 34
ESEA: Discovering the Dysregulated Pathways based on Edge Set Enrichment Analysis
Han, J., Shi, X., Zhang, Y., Xu, Y., Jiang, Y., Zhang, C., Li, F., Yang, H., Shang, D., Sun, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep13044 · Cited by 35
Loss of HSF1 Results in Defective Radiation-Induced G2Arrest and DNA Repair
Li, Q., & Martinez, J. D. (2011) · Radiation Research · doi:10.1667/rr2393.1 · Cited by 35
Detection of mutant p53 using field-effect transistor biosensor
Han, S. H., Kim, S. K., Park, K., Yi, S. Y., Park, H. J., Lyu, H., Kim, M., & Chung, B. H. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2010.03.006 · Cited by 34
Arsenic-induced apoptosis in the p53-proficient and p53-deficient cells through differential modulation of NFkB pathway
Yin, L., & Yu, X. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.06.053 · Cited by 34
Wild-Type p53 Attenuates Cancer Cell Motility by Inducing Growth Differentiation Factor-15 Expression
Cheng, J., Chang, H., & Leung, P. C. K. (2011) · Endocrinology · doi:10.1210/en.2011-0059 · Cited by 34
Identification of a Novel Germ Line Variant Hotspot Mutant p53-R175L in Pediatric Adrenal Cortical Carcinoma
West, A. N., Ribeiro, R. C., Jenkins, J., Galindo, C. R., de Figueiredo, B. C., Kriwacki, R. W., & Zambetti, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4580 · Cited by 32
Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology
Li, Q., Li, G., Li, P., Wang, H., Fang, X., He, T., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101155 · Cited by 35
Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma
Hirotsu, Y., Zheng, T., Amemiya, K., Mochizuki, H., Guleng, B., & Omata, M. (2016) · Hepatology Research · doi:10.1111/hepr.12663 · Cited by 32
Tumor suppressor p53 restrains cancer cell dissemination by modulating mitochondrial dynamics
Phan, T. T. T., Lin, Y., Chou, Y., Wu, C., & Lin, L. (2022) · Oncogenesis · doi:10.1038/s41389-022-00401-x · Cited by 34
Low-level p53 expression changes transactivation rules and reveals superactivating sequences
Jordan, J. J., Menéndez, D., Sharav, J., Beno, I., Rosenthal, K., Resnick, M. A., & Haran, T. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205971109 · Cited by 33
Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low DNA Content
Milbury, C. A., Chen, C. C., Mamon, H. J., Liu, P., Santagata, S., & Makrigiorgos, G. M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.008 · Cited by 33

Authors: Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P.
Affiliations: World Health Organization (CH)
German Cancer Research Center (DE)
National Institutes of Health (US)
Corresponding author: Hainaut, Pierre
ORCID: Olivier, Magali
Harris, Curtis C.
Hainaut, Pierre
Venue: Human Mutation
Publisher: Wiley
Published: 2002-05-03
Volume: 19
Issue: 6
Pages: 607-614
ISSN: 1059-7794 (ISSN-L)
1098-1004
DOI: 10.1002/humu.10081
OpenAlex: W2073576377
Cited by: 1,248
References: 14
Citations by year: 2026: 11 · 2025: 20 · 2024: 33 · 2023: 46 · 2022: 33 · 2021: 33 · 2020: 32 · 2019: 31 · 2018: 40 · 2017: 30 · 2016: 37 · 2015: 34 · 2014: 48 · 2013: 43 · 2012: 61
FWCI: 29.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4869 d)
Locations: Human Mutation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: TP53 mutation, somatic mutations, TP53 polymorphisms, mutation patterns, cancer genomics, carcinogen exposure, viral infection, genetic background, database restructuring
MeSH terms: DNA Mutational Analysis, Humans, Mutation, Genes, Tumor Suppressor, Genes, p53, Li-Fraumeni Syndrome, Computational Biology, Internet, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The IARC TP53 database: New online mutation analysis and recommendations to users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks